Genitourinary tumours, non-prostate 2

LBA28 - STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)

Janet E. Brown, et al.

Conclusions

Although OS just fell short of overall defined NI using this rigorous approach, probably due to fewer than expected events, QALY NI was demonstrated and a DFIS was seen to be acceptable to patients and clinicians. DFIS also appeared to be highly cost-effective compared to CCS.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA28.html.pdf

 

LBA29 - Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)

Naveen S. Vasudev, et al.

Conclusions

Giving IPI 12-weekly, instead of 3-weekly, in combination with N, was associated with a clinically significant reduction in rates of G3/4 trAE. Outcome data suggested there was no clear reduction in ORR or PFS with the modified schedule and is in line with previous comparative studies with sunitinib.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA29.html.pdf

 

653O - Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564

Toni K. Choueiri, et al.

Conclusions

No clinically meaningful changes from baseline in health-related QoL or symptom scores were observed with adjuvant pembro or placebo. These scores remained stable over time. PRO findings suggested that adjuvant pembro was tolerable from a pt perspective.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/653O.html.pdf

 

LBA30 - Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10

Alexandros Papachristofilou, et al.

Conclusions

No clinically meaningful changes from baseline in health-related QoL or symptom scores were observed with adjuvant pembro or placebo. These scores remained stable over time. PRO findings suggested that adjuvant pembro was tolerable from a pt perspective.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA30.html.pdf